204 related articles for article (PubMed ID: 36702170)
1. Allergen immunotherapy for allergic asthma: The future seems bright.
Diamant Z; van Maaren M; Muraro A; Jesenak M; Striz I
Respir Med; 2023; 210():107125. PubMed ID: 36702170
[TBL] [Abstract][Full Text] [Related]
2. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
Hesse L; Petersen AH; Nawijn MC
Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
[TBL] [Abstract][Full Text] [Related]
3. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
[TBL] [Abstract][Full Text] [Related]
4. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
6. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
Eifan AO; Calderon MA; Durham SR
Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
[TBL] [Abstract][Full Text] [Related]
7. Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling.
Batard T; Canonica WG; Pfaar O; Shamji MH; O'Hehir RE; van Zelm MC; Mascarell L
Mol Immunol; 2023 Mar; 155():124-134. PubMed ID: 36806944
[TBL] [Abstract][Full Text] [Related]
8. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
9. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
[TBL] [Abstract][Full Text] [Related]
10. Real-world study: drug reduction in children with allergic rhinitis and asthma receiving immunotherapy.
Sánchez J; Alvarez L; García E
Immunotherapy; 2023 Mar; 15(4):253-266. PubMed ID: 36789565
[TBL] [Abstract][Full Text] [Related]
11. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
[TBL] [Abstract][Full Text] [Related]
12. Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy.
Yang L; Yang Y; Xu Q; Zhang W; Jiang Q; Li W; Wang Y; Ma D; Lin X; Sun B; Zhu R
Front Immunol; 2021; 12():786738. PubMed ID: 35197963
[TBL] [Abstract][Full Text] [Related]
13. House dust mite sublingual immunotherapy in allergic rhinitis.
Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
[TBL] [Abstract][Full Text] [Related]
14. Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.
Woehlk C; Ramu S; Sverrild A; Nieto-Fontarigo JJ; Vázquez-Mera S; Cerps S; Pulga A; Andreasson LM; Eriksen LL; Dyhre-Petersen N; Menzel M; Klein DK; Hansen S; Uller L; Porsbjerg C
Am J Respir Crit Care Med; 2023 May; 207(9):1161-1170. PubMed ID: 36701676
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma.
Farraia M; Paciência I; Castro Mendes F; Cavaleiro Rufo J; H Shamji M; Agache I; Moreira A
Allergy; 2022 Sep; 77(9):2688-2698. PubMed ID: 35451128
[TBL] [Abstract][Full Text] [Related]
16. Tablet-based sublingual immunotherapy for respiratory allergy.
Prieto L
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():30-35. PubMed ID: 29146015
[TBL] [Abstract][Full Text] [Related]
17. Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy.
Bordas-Le Floch V; Berjont N; Batard T; Varese N; O'Hehir RE; Canonica WG; van Zelm MC; Mascarell L
Allergy; 2022 Apr; 77(4):1263-1273. PubMed ID: 34551124
[TBL] [Abstract][Full Text] [Related]
18. Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis.
Jordakieva G; Kundi M; Lemell P; Zieglmayer R; Zieglmayer P; Godnic-Cvar J; Jensen-Jarolim E
Sci Rep; 2017 May; 7(1):2555. PubMed ID: 28566688
[TBL] [Abstract][Full Text] [Related]
19. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
[TBL] [Abstract][Full Text] [Related]
20. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
